It is a common form of heart failure in patients with obesity, hypertension, and metabolic syndrome, and it has become a recognized clinical target for incretin-based therapy following the STEP-HFpEF trial (semaglutide in HFpEF with obesity) and the SUMMIT trial (tirzepatide in obesity-related HFpEF)
Without a clear clinical pathway, GLP-1 usage becomes indefinite and so does the cost
Ready to bridge the gap between your medication and your performance
No, maintenance sessions are recommended since glutathione levels naturally fluctuate based on diet, stress, and environmental factors
Proctor CJC Pediatric and Congenital Heart Disease.2026
Direct Meds is a telehealth platform that connects patients with licensed physicians who can evaluate whether a compounded GLP-1 medication may be appropriate for their individual needs and, if prescribed, facilitate access to it with shipping included